Related Experiment Video

Updated: Jul 18, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

Neurohormonal activation and left ventricular ejection fraction in patients with suspected myocardial ischemia

Juerg Wermuth1, Daniel Staub, Kirsten Laule-Kilian

  • 1Department of Internal Medicine, Medical Division A, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.

International Journal of Cardiology
|December 22, 2006
PubMed

Insights

B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) have a weak correlation in patients with suspected coronary artery disease. This association is influenced by myocardial scar presence and sex, indicating different diagnostic windows.

Area of Science:

  • Cardiology
  • Biomarkers
  • Diagnostic Imaging

Background:

  • B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) are vital in managing suspected coronary artery disease (CAD).
  • Limited data exists on the association between BNP and LVEF in this patient population.

Purpose of the Study:

  • To investigate the correlation between BNP and LVEF in patients with suspected myocardial ischemia.
  • To explore factors influencing the BNP-LVEF relationship, including myocardial scar and sex.

Main Methods:

  • BNP and LVEF were measured in 260 patients undergoing myocardial perfusion SPECT.
  • Spearman's correlation test was used to analyze the association between BNP and LVEF.
  • Subgroup analyses were performed based on myocardial scar presence and sex.

Main Results:

  • A statistically significant but weak overall correlation (r=0.274) was found between BNP and LVEF.
  • The correlation was moderate in patients with myocardial scar (r=-0.540) and men (r=-0.503), but weak or non-existent in those without scar (r=0.185) or women.
  • BNP was not an accurate standalone test for detecting left ventricular systolic dysfunction (AUC=0.643).

Conclusions:

  • BNP and LVEF exhibit a weak correlation in patients with suspected myocardial ischemia.
  • Myocardial scar and sex significantly influence the relationship between BNP and LVEF.
  • Neurohormonal (BNP) and morphologic (LVEF, scar) assessments offer complementary insights into cardiac status.
Abstract

More Related Videos

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...